EMG
XLRN

Ellington Management Group’s Acceleron Pharma XLRN Stock Holding History

Ellington Management Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,600
Closed -$435K – 721
2014
Q1 		$435K Buy
+12,600
New +$569K 0.13% 245

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ellington Management Group's XLRN Position: Q2 2014 in Review

Ellington Management Group sold out of Acceleron Pharma (XLRN) in Q2 2014, closing a stake of 12,600 shares — an estimated $435K sold.

Ellington Management Group first reported a position in XLRN in Q1 2014 and held it in 1 quarter. The position peaked at $435K in Q1 2014. 91 funds tracked by Wall St. Rank hold XLRN as of Q2 2014.

  • Ellington Management Group reported no remaining Acceleron Pharma position as of Q2 2014 after selling out during the quarter.
  • Ellington Management Group sold 12,600 Acceleron Pharma shares in Q2 2014, an estimated $435K.
  • Ellington Management Group first reported a position in Acceleron Pharma in Q1 2014 and held it in 1 quarter.
  • Ellington Management Group's Acceleron Pharma position peaked at $435K in Q1 2014.
  • 91 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2014.

Based on Ellington Management Group's 13F filing for Q2 2014, filed 14 Aug 2014.